We are a French pharmaceutical group that has been supporting healthcare professionals specialized in Diagnostic and Interventional Medical Imaging since 1926. We develop and market contrast media, delivery systems, medical devices and related solutions adapted to their needs. Guerbet is listed in Euronext Segment B, and a majority of its shares are owned by the Guerbet family.
Every second, somewhere in the world a patient undergoes an imaging procedure with a Guerbet product. More than 60,000 health professionals rely on our contrast agents to diagnose disease and assess treatment efficacy.
Our products and services are made available in more than 80 countries through our affiliates and network of distributors.
Advancing in innovative solutions is at the heart of Guerbet’s mission and we dedicate 10% of our revenue to R&D. We are focusing on the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system) and interventional radiology. 395 patents are owned and pending. 7 products have been launched in the last 2 years.